Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Publisher Name :
Date: 15-Dec-2013
No. of pages: 89

GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.

Scope


  • A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.

  • In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.

  • A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.

  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.

  • Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.

  • Discussion of the drivers and barriers for market growth.

  • In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.


Reasons to buy

  • Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.

  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.

  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.

  • Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.

  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 13
2.7.1 Chemotherapy 13
2.7.2 Targeted Therapies 14
2.7.3 Resistance to Pharmacological Therapies 15
2.7.4 Treatment Guidelines 15

3 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Marketed Products 18
3.1 Avastin (Bevacizumab) - Hoffman La Roche 18
3.2 Erbitux (Cetuximab) - Bristol-Myers Squibb, Eli Lilly, and Merck KGaA 19
3.3 Vectibix (Panitumumab) - Amgen and Takeda 21
3.4 Heat Map for Marketed Products 22
3.5 Conclusion 24

4 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Developmental Pipeline 25
4.1 Overall Pipeline 25
4.2 Molecular Targets and Mechanisms of Action 27
4.3 Clinical Trials 28
4.3.1 Failure Rate 28
4.3.2 Clinical Trial Size 29
4.3.3 Duration 32
4.3.4 Primary Endpoints 33
4.4 Conclusion 35
4.5 Key Late-Stage Pipeline Products 35
4.5.1 IMC-1121B (Ramucirumab) - Eli Lilly and Company 35
4.5.2 Xilonix - XBiotech 36
4.5.3 MetMAb (Onartuzumab) - Hoffmann-La Roche 36
4.5.4 Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo 36
4.5.5 MK0646 (Dalotuzumab) - Merck 37
4.5.6 AMG-655 (Conatumumab) - Amgen 37
4.6 Conclusion 37

5 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Market Forecast to 2019 38
5.1 Global 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Market Size 40
5.2 North America 41
5.2.1 US 41
5.2.2 Canada 43
5.3 Europe 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 47
5.4 Japan 48
5.4.1 Treatment Usage Patterns 48
5.4.2 Market Size 49
5.5 Drivers and Barriers 49
5.5.1 Drivers 49
5.5.2 Barriers 50

6 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Deals and Strategic Consolidations 52
6.1 R&D Licensing Agreements 52
6.1.1 Key Licensing Deals 55
6.2 Co-Development Agreements 57
6.2.1 Key Co-Development Agreements 58

7 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Appendix 59
7.1 Market Definitions 59
7.2 Abbreviations 59
7.3 References 62
7.4 Sources for Heat Map 66
7.5 All Pipeline Products, by Stage of Development 67
7.5.1 Discovery 67
7.5.2 Preclinical and IND/CTA-filed 68
7.5.3 Phase I 73
7.5.4 Phase II 76
7.5.5 Phase III and Pre-registration 81
7.5.6 Undisclosed 82
7.6 Tabular Forecast Data 83
7.6.1 Global 83
7.6.2 US 83
7.6.3 Canada 83
7.6.4 UK 83
7.6.5 France 84
7.6.6 Germany 84
7.6.7 Italy 84
7.6.8 Spain 84
7.6.9 Japan 85
7.7 Research Methodology 85
7.7.1 Coverage 85
7.7.2 Secondary Research 85
7.7.3 Primary Research 86
7.7.4 Therapeutic Landscape 86
7.7.5 Epidemiology-Based Forecasting 86
7.7.6 Market Size by Geography 88
7.7.7 Geographical Landscape 89
7.7.8 Pipeline Analysis 89
7.8 Contact Us 89
7.9 Disclaimer 89

List of Tables

Table 1: Market for mAbs in Colorectal Cancer, US, Epidemiology, 2008 10
Table 2: Market for mAbs in Colorectal Cancer, US, Diagnosis by Stage, 2009 10
Table 3: Market for mAbs in Colorectal Cancer, US, Five-Year Survival by Stage, 2009 12
Table 4: Market for mAbs in Colorectal Cancer, Global, TNM Staging, 2013 13
Table 5: Market for mAbs in Colorectal Cancer, Sources for Heat Map 66
Table 6: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 67
Table 7: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 68
Table 8: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 73
Table 9: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 76
Table 10: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 81
Table 11: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 82
Table 12: Market for mAbs in Colorectal Cancer, Global, Forecast Data, 2012-2019 83
Table 13: Market for mAbs in Colorectal Cancer, US, Forecast Data, 2012-2019 83
Table 14: Market for mAbs in Colorectal Cancer, Canada, Forecast Data, 2012-2019 83
Table 15: Market for mAbs in Colorectal Cancer, UK, Forecast Data, 2012-2019 83
Table 16: Market for mAbs in Colorectal Cancer, France, Forecast Data, 2012-2019 84
Table 17: Market for mAbs in Colorectal Cancer, Germany, Forecast Data, 2012-2019 84
Table 18: Market for mAbs in Colorectal Cancer, Italy, Forecast Data, 2012-2019 84
Table 19: Market for mAbs in Colorectal Cancer, Spain, Forecast Data, 2012-2019 84
Table 20: Market for mAbs in Colorectal Cancer, Japan, Forecast Data, 2012-2019 85

List of Figures

Figure 1: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage I to III) 16
Figure 2: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage IV) 17
Figure 3: Market for mAbs in Colorectal Cancer, Global, Sales of Avastin ($bn), 2004-2012 19
Figure 4: Market for mAbs in Colorectal Cancer, Global, Sales of Vectibix ($m), 2006-2012 21
Figure 5: Market for mAbs in Colorectal Cancer, Global, Heat Map of Safety and Efficacy for Marketed Products, 2013 23
Figure 6: Market for mAbs in Colorectal Cancer, Global, Overall Pipeline, 2013 26
Figure 7: Market for mAbs in Colorectal Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013 27
Figure 8: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 28
Figure 9: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 29
Figure 10: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes, 2006-2013 30
Figure 11: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013 31
Figure 12: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations, 2006-2013 32
Figure 13: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013 33
Figure 14: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 34
Figure 15: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 35
Figure 16: Market for mAbs in Colorectal Cancer, Global, Market Growth and Size, 2012-2019 38
Figure 17: Market for mAbs in Colorectal Cancer, Global, Treatment Patterns, 2012-2019 39
Figure 18: Market for mAbs in Colorectal Cancer, Global, Market Size ($bn), 2012-2019 40
Figure 19: Market for mAbs in Colorectal Cancer, US, Treatment Usage Patterns, 2012-2019 41
Figure 20: Market for mAbs in Colorectal Cancer, US, Market Size ($m), 2012-2019 42
Figure 21: Market for mAbs in Colorectal Cancer, Canada, Treatment Usage Patterns, 2012-2019 43
Figure 22: Market for mAbs in Colorectal Cancer, Canada, Market Size ($m), 2012-2019 44
Figure 23: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Treatment Patterns, 2012-2019 45
Figure 24: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Annual Cost of Therapy, 2012-2019 46
Figure 25: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Market Size ($m), 2012-2019 47
Figure 26: Market for mAbs in Colorectal Cancer, Japan, Treatment Usage Patterns, 2012-2019 48
Figure 27: Market for mAbs in Colorectal Cancer, Japan, Market Size ($m), 2012-2019 49
Figure 28: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 52
Figure 29: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 53
Figure 30: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 54
Figure 31: Market for mAbs in Colorectal Cancer, Global, Co-development Deals Global Network, 2006-2013 57
Figure 32: Market for mAbs in Colorectal Cancer, Global, Co-development Deals by Year and Value, 2006-2013 58
Figure 33: GBI Research Market Forecasting Model 88

  • Overview of Global and Chinese 3D Printing Market 2015-2020
    ‘2015 3D Printing Industry Report -Global and Chinese Market’ is a comprehensive research report that describes the scope of the Global and Chinese 3D printing industry, analyzing the end-users behavior and the latest industry trends. Also, the report evaluates the growth prospects and the up-coming opportunities in the industry over the forecast period of 2015-2020. [...]
  • Schottky Diode Industry Research – 2015 Global and Chinese Market Overview
    ‘2015 Schottky Diode Industry Report – Global and Chinese Market Scenario’ is a top-notch research report, delivering premium industry insights and explanations of complex business scenarios. The report systematically articulates various growth prospects and current market challenges being faced by the existing industry players. The research report also drafts a meticulous business forecast that provides [...]
  • Codeine (CAS 76-57-3) Industry Research Report – 2009-2019 Market Forecast
    ‘Global and Chinese Codeine (CAS 76-57-3) Industry, 2009-2019 Market Research Report’, a systematically structured research report, that aims to deliver a detailed understanding of vivid market scenarios prevalent in the Codeine (CAS 76-57-3) industry to the user.  The report articulates various sections that thoroughly describe all key-aspects of the Codeine (CAS 76-57-3) industry. The report [...]
  • Global and Chinese Mainframe Banking Industry 2015 Outlook
    2015 Banks Mainframe Industry Report -Global and Chinese Market is a detailed market research report, delivering premium industry insights and analyzing the growth prospects of the industry over the forecast period of 2015-2020. The systematically structured sections of the research report, aims at conveying a strong business understanding to the user, enhancing the decision making [...]
  • Global and Chinese Market Situation of Milk Infant Formula Industry Over the Period of 2009-2019
    ‘Market Research Report on Global and Chinese Milk Infant Formula Industry, 2009-2019’ a comprehensive market study, that analyses various market landscape and key-aspects of the industry, delivering premium business insight and thorough understanding of the Global and Chinese market conditions to the user. Industry experts have methodologically structured the elaborative sections of the research report, [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • The New Generation of Antibody Therapeutics: Current Status and Future Prospects
    Published: 06-Jan-2012        Price: US 2495 Onwards        Pages: 124
    Antibody sales are predicted to reach $50 billion this year. This Insight Pharma Report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. Following a review of the business environment and market forces, this report examines: The state of the art, and the needs and direction, of antibody technology today Antibody conjugates and other payloa......
  • Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
    Published: 12-Jan-2012        Price: US 2300 Onwards        Pages: 118
    This report gives a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development (Preclinical and Phase 1). In contrast, there are just 9 candidates at Phase 3, while there are 31 at Phase 2. These developments are being progressed by 66 companies, of which nine (14%) are major intern......
  • Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016
    Published: 20-Jan-2012        Price: US 1000 Onwards        Pages: 78
    Advancements in antibody technology has revolutionized both the diagnostic and therapeutic sciences. As of today, monoclonal antibodies can be produced virtually against any antigen and they have transformed the diagnostic industry in view of their specificity towards specific antigens and almost unlimited production capabilities. In the field of therapeutics, they have changed the treatment possibilities and significantly improved the life expectancies of patients who were earlier having very h......
  • Research Report on Chinese Monoclonal Antibody Industry, 2012
    Published: 07-Mar-2012        Price: US 3000 Onwards        Pages: 50
    Antibody medicine is generally obtained from monoclonal antibody through genetic engineering, possessing the advantages of strong targeting and few drug side effects. At the present time, it is mainly used for the cure of tumor and immune system diseases and has good application prospects in clinical treatment. From the point of the global market, antibody medicine accounts for over 40% of the entire biotechnology medicine. With constant growth of the market share, antibody medicine has become t......
  • Global and China Monoclonal Antibody Industry Report, 2013
    Published: 01-Jan-2013        Price: US 2500 Onwards        Pages: 100
    In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Joh......
  • 2013 Deep Research Report on China Human Immunoglobulin Industry
    Published: 18-Mar-2013        Price: US 1800 Onwards        Pages: 116
    This is a professional and depth research report on China Human Immunoglobulin industry. This report has firstly introduced Human Immunoglobulin definition classification industry chain etc related information. Then introduced Human Immunoglobulin manufacturing technology and product specifications, And then summary statistics China major Human Immunoglobulin manufacturers 2010-2016 Human Immunoglobulin capacity production supply demand shortage and Human Immunoglobulin selling price cost gross ......
  • Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022
    Published: 30-Apr-2013        Price: US 3495 Onwards        Pages: 48
    GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contact with......
  • Research Report on Global and China Monoclonal Antibody Industry, 2013-2017
    Published: 02-Aug-2013        Price: US 2200 Onwards        Pages: 50
    Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most i......
  • Patrys Limited - Product Pipeline Review - 2013
    Published: 30-Sep-2013        Price: US 1500 Onwards        Pages: 49
    Global Market Direct's pharmaceuticals report, "Patrys Limited Product Pipeline Review 2013" provides data on the Patrys Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Patrys Limited's corporate website, SEC filings, investor presentations and fe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs